29 citations
,
July 2009 in “BJU international” This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.
29 citations
,
January 1996 in “Journal of Pharmaceutical Sciences” This study developed a theoretical model that suggests finasteride may completely inhibit 5AR type 2, but not sufficiently suppress type 1, leading to only partial reduction of dihydrotestosterone at clinical doses.
11 citations
,
January 2017 in “Journal of Endocrinology/Journal of endocrinology” This study observed that female mice with disrupted 5α-reductase 1 showed increased insulin resistance and hepatic steatosis, suggesting altered glucocorticoid metabolism contributes to metabolic disorders.
11 citations
,
May 1996 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study reported that 5 alpha-reductase type 2 is the predominant enzyme in pubic skin fibroblasts across normal men, women, and hirsute patients, suggesting potential treatment options for idiopathic hirsutism.
10 citations
,
August 2014 in “Skin research and technology” This study found that variations in sleep patterns, free testosterone, and 5-alpha-reductase type 1 activity are associated with changes in sebum excretion in women, which may contribute to variability in acne studies.